Figure 1
Concentration–time profiles of capecitabine and its metabolites in patients with advanced breast cancer. Patients received 1250 mg capecitabine m−2 orally with tap water before collecting plasma samples and interstitial tissue fluid up to 5 h after administration. Concentration–time profile in plasma (A), concentration–time profile in the interstitium of malignant tissue (B), concentration–time profile in the interstitium of subcutaneous connective tissue (C). Concentrations are depicted as means of the single courses ± s.e. (n=10). 5′-DFCR=5′-deoxy-5-fluorocytidine; 5′-DFUR=5′-deoxy-5-fluorouridine; 5-FU=5-fluorouracil.
